Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endocrine changes in Alzheimer's disease.

M Davidson1, L Bastiaens, B M Davis

  • 1Bronx Veterans Administration Medical Center, New York.

Neurologic Clinics
|February 1, 1988
PubMed
Summary

Current research shows no consistent endocrine abnormalities in Alzheimer's disease patients. However, assessing neuroendocrine function may reveal specific neurotransmission issues, guiding targeted Alzheimer's pharmacologic strategies for better outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Research and development of a silicone letrozole-releasing device to control reproduction in cattle.

Theriogenology·2020
Same author

Corrigendum to "Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension" [Mitochondrion 36 (2017) 114-123].

Mitochondrion·2019
Same author

Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma.

Journal of controlled release : official journal of the Controlled Release Society·2019
Same author

Automatic quantitative analysis of experimental primary and secondary retinal neurodegeneration: implications for optic neuropathies.

Cell death discovery·2016
Same author

Towards maximising information extraction from rodent models of ocular disease.

Cell death & disease·2016
Same author

TRAF family member-associated NF-kappa B activator (TANK) expression increases in injured sensory neurons and is transcriptionally regulated by Sox11.

Neuroscience·2012

Area of Science:

  • Neuroendocrinology
  • Alzheimer's Disease Research
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Endocrine and neuroendocrine functions are complex and can be affected by neurological conditions.
  • Understanding these functions in AD is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate potential endocrine abnormalities in Alzheimer's disease patients.
  • To explore the utility of neuroendocrine function assessment in identifying patient subpopulations.
  • To determine if specific neuroendocrine responses predict therapeutic benefits from pharmacologic interventions.

Main Methods:

  • The study involved assessing neuroendocrine function in patients with Alzheimer's disease.

Related Experiment Videos

  • Specific tests likely included measurements of hormone levels and responses to stimuli.
  • Patient responses to cholinomimetic drugs were correlated with symptomatic benefit.

    • Main Results:

    • No consistent endocrine abnormalities were detected in the majority of Alzheimer's disease patients.
    • Neuroendocrine function assessment showed potential for identifying subgroups with specific neurotransmission abnormalities.
    • A notable finding was that patients showing the greatest plasma cortisol elevation in response to cholinomimetic drugs experienced the most symptomatic improvement.

    Conclusions:

    • At present, no definitive endocrine abnormalities are consistently found in Alzheimer's disease.
    • Neuroendocrine assessment can identify patient subpopulations likely to respond to specific pharmacologic strategies.
    • Cortisol response to cholinomimetic drugs may predict symptomatic benefit, guiding personalized Alzheimer's treatment.